Mylan and Pfizer have come up with the final combination for the board of directors of Viatris – the company that will be created from the merger of the latter’s off-patent manufacturing business, Upjohn, with Mylan.
Viatris, which is expected to launch in mid-2020, subject to regulatory approval, will possess a portfolio of prescription medicines, complex generics, and over-the-counter drug products.
On Pfizer’s side, Ian Read and Jim Kilts will run the newly formed company as members of its board of directors, while W. Don Cornwell will resign from the Pfizer board to serve as a director of Viatris.
Mylan will have eight of its own directors serving on the Viatris board, including JoEllen Lyons Dillon, Neil Dimick, Melina Higgins, Harry Korman, Rajiv Malik, Richard Mark, Mark Parrish and Pauline Mohr.
Finally, the board of Viatris will include executive chairman, Robert Coury, and the role of CEO will be taken over by Michael Goettler.
Goettler, who is currently group president of Upjohn, has been with Pfizer since 2009, after the latter’s acquisition of Wyeth.